Silence Therapeutics (NASDAQ:SLN – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $80.00 price target on the stock.
Several other research firms have also commented on SLN. Robert W. Baird boosted their price objective on shares of Silence Therapeutics from $50.00 to $53.00 in a research report on Thursday, January 26th. Morgan Stanley started coverage on shares of Silence Therapeutics in a research note on Friday, December 9th. They issued an “equal weight” rating and a $18.00 target price for the company. Finally, Chardan Capital cut their target price on shares of Silence Therapeutics from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday.
Silence Therapeutics Stock Down 3.2 %
Silence Therapeutics stock opened at $8.70 on Friday. Silence Therapeutics has a 52 week low of $7.80 and a 52 week high of $21.32. The firm’s 50-day simple moving average is $12.34 and its 200 day simple moving average is $12.61. The firm has a market capitalization of $260.39 million, a PE ratio of -5.58 and a beta of 0.88.
Institutional Inflows and Outflows
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.